Compare ALDX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALDX | NSRX |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | Israel |
| Employees | 6 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 37.1M |
| IPO Year | 2014 | 2024 |
| Metric | ALDX | NSRX |
|---|---|---|
| Price | $0.64 | $3.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $6.60 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 1.8M | 23.8K |
| Earning Date | 11-04-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $1.98 |
| 52 Week High | $5.93 | $9.50 |
| Indicator | ALDX | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.32 | 50.98 |
| Support Level | N/A | $2.97 |
| Resistance Level | $1.58 | $3.60 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.12 | 48.14 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.